MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Phase 3
Recruiting
Conditions
Episodic Migraine
Interventions
First Posted Date
2023-09-21
Last Posted Date
2025-04-30
Lead Sponsor
Ipsen
Target Recruit Count
714
Registration Number
NCT06047457
Locations
🇺🇸

SDS Clinical Trials, Orange, California, United States

🇩🇪

Emovis GmbH, Berlin, Germany

🇺🇸

Central Research Associates, Birmingham, Alabama, United States

and more 89 locations

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Phase 3
Recruiting
Conditions
Chronic Migraine
Interventions
First Posted Date
2023-09-21
Last Posted Date
2025-04-30
Lead Sponsor
Ipsen
Target Recruit Count
720
Registration Number
NCT06047444
Locations
🇮🇹

IRCCS San Raffaele Pisana, Roma, Italy

🇮🇹

PU Campus Bio-Medico di Roma, Roma, Italy

🇵🇱

Synexus Polska Sp. z o.o., Gdynia, Poland

and more 109 locations

Botulinum Toxin for Chronic Neuropathic Pain

Recruiting
Conditions
Neuralgia
Chronic Pain
Interventions
First Posted Date
2023-09-13
Last Posted Date
2023-09-13
Lead Sponsor
Region Zealand
Target Recruit Count
12
Registration Number
NCT06036043
Locations
🇩🇰

University Hospital of regions Zealand, Køge, Denmark

A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

Phase 2
Completed
Conditions
COPD
Interventions
First Posted Date
2023-08-21
Last Posted Date
2024-07-17
Lead Sponsor
RMW Testing
Target Recruit Count
40
Registration Number
NCT06003049
Locations
🇺🇸

Tranquil Clinical Research, Webster, Texas, United States

To Evaluate the Efficacy and Safety of LIZTOX in Subjects With Benign Masseteric Hypertrophy

Phase 3
Recruiting
Conditions
Benign Masseteric Hypertrophy
Interventions
Drug: normal Saline
First Posted Date
2023-07-27
Last Posted Date
2023-07-27
Lead Sponsor
Huons Biopharma
Target Recruit Count
168
Registration Number
NCT05964257
Locations
🇰🇷

Chung-Ang University Hospital, Dongjak, Seoul, Korea, Republic of

Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia

Phase 1
Active, not recruiting
Conditions
Spasmodic Dysphonia
Interventions
First Posted Date
2023-06-07
Last Posted Date
2025-02-25
Lead Sponsor
University of Florida
Target Recruit Count
36
Registration Number
NCT05892770
Locations
🇺🇸

University of Florida- Shands Hospital, Gainesville, Florida, United States

The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity

Phase 4
Withdrawn
Conditions
Spasticity, Muscle
Cerebrovascular Disorders
Botulinum Toxin
Interventions
First Posted Date
2023-06-02
Last Posted Date
2023-11-22
Lead Sponsor
Sisli Hamidiye Etfal Training and Research Hospital
Registration Number
NCT05887479

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

Phase 2
Recruiting
Conditions
Urologic Diseases
Overactive Bladder Syndrome
Urinary Incontinence
Overactive Bladder
Interventions
First Posted Date
2023-05-30
Last Posted Date
2024-07-03
Lead Sponsor
Northwestern University
Target Recruit Count
80
Registration Number
NCT05878951
Locations
🇺🇸

Northwestern Medicine, Chicago, Illinois, United States

Assessment of Botulinum Toxin Injection for Treatment of Temporomandibular Joint Dislocation

Not Applicable
Recruiting
Conditions
Subluxation of Temporomandibular Joint
Dislocation of Temporomandibular Joint TMJ
Interventions
First Posted Date
2023-05-18
Last Posted Date
2023-05-22
Lead Sponsor
Cairo University
Target Recruit Count
28
Registration Number
NCT05863286
Locations
🇪🇬

Faculty of Dentistry, Cairo university, Cairo, Elmanial, Cairo, Egypt

Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles

Phase 4
Completed
Conditions
Face
Rejuvenation
Skin Fold
Interventions
Drug: Onabotulinum toxin A
First Posted Date
2023-05-03
Last Posted Date
2023-05-03
Lead Sponsor
Instituto de Oftalmología Fundación Conde de Valenciana
Target Recruit Count
26
Registration Number
NCT05840445
Locations
🇲🇽

Institute of Ophthalmology, Conde de Valenciana Foundation, Mexico, City, Mexico City, Mexico

🇲🇽

Instituto de Oftalmología, Mexico City, Mexico

© Copyright 2025. All Rights Reserved by MedPath